| Literature DB >> 27974665 |
Léon C L van Kempen1,2, Margaret Redpath1,2, Mounib Elchebly2, Kathleen Oros Klein2, Andreas I Papadakis1,2, James S Wilmott3, Richard A Scolyer3, Per-Henrik Edqvist4, Fredrik Pontén4, Dirk Schadendorf5,6, Anke F van Rijk2, Stefan Michiels7,8, Anne Dumay9, Anne Helbling-Leclerc10,11, Philippe Dessen12, Jasper Wouters13,14,15, Marguerite Stass16, Celia M T Greenwood2,17,18, Ghanem E Ghanem19, Joost van den Oord13, Jean Feunteun11, Alan Spatz20,2,17.
Abstract
Male gender is independently and significantly associated with poor prognosis in melanoma of all clinical stages. The biological underpinnings of this sex difference remain largely unknown, but we hypothesized that gene expression from gonosomes (sex chromosomes) might play an important role. We demonstrate that loss of the inactivated X chromosome in melanomas arising in females is strongly associated with poor distant metastasis-free survival, suggesting a dosage benefit from two X chromosomes. The gonosomal protein phosphatase 2 regulatory subunit B, beta (PPP2R3B) gene is located on the pseudoautosomal region (PAR) of the X chromosome in females and the Y chromosome in males. We observed that, despite its location on the PAR that predicts equal dosage across genders, PPP2R3B expression was lower in males than in females and was independently correlated with poor clinical outcome. PPP2R3B codes for the PR70 protein, a regulatory substrate-recognizing subunit of protein phosphatase 2A. PR70 decreased melanoma growth by negatively interfering with DNA replication and cell cycle progression through its role in stabilizing the cell division cycle 6 (CDC6)-chromatin licensing and DNA replication factor 1 (CDT1) interaction, which delays the firing of origins of DNA replication. Hence, PR70 functionally behaves as an X-linked tumor suppressor gene.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27974665 DOI: 10.1126/scitranslmed.aai9188
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956